The latest price target for Merck & Co (NYSE:MRK) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $155.00 expecting MRK to rise to within 12 months (a possible 34.20% upside). 41 analyst firms have reported ratings in the last year.

The latest analyst rating for Merck & Co (NYSE:MRK) was provided by Cantor Fitzgerald, and Merck & Co reiterated their overweight rating.

The last upgrade for Merck & Co Inc happened on January 4, 2024 when TD Cowen raised their price target to $135. TD Cowen previously had a market perform for Merck & Co Inc.

The last downgrade for Merck & Co Inc happened on March 11, 2024 when Societe Generale changed their price target from N/A to $104 for Merck & Co Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Merck & Co, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Merck & Co was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Merck & Co (MRK) rating was a reiterated with a price target of $155.00 to $155.00. The current price Merck & Co (MRK) is trading at is $115.50, which is out of the analyst’s predicted range.